{"id":"cetuximab-egfr-inhibitor","safety":{"commonSideEffects":[{"rate":"80–90","effect":"Acneiform rash"},{"rate":"25–30","effect":"Diarrhea"},{"rate":"20–25","effect":"Nausea"},{"rate":"15–20","effect":"Fatigue"},{"rate":"3–5","effect":"Infusion reactions"},{"rate":"13–17","effect":"Hypomagnesemia"},{"rate":"5–10","effect":"Paronychia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetuximab competitively inhibits ligand binding to EGFR, a receptor tyrosine kinase frequently overexpressed in solid tumors. By blocking EGFR activation, it suppresses downstream signaling pathways (MAPK and PI3K/AKT) that drive cell proliferation, survival, and angiogenesis. This leads to cell cycle arrest and apoptosis in EGFR-dependent tumors.","oneSentence":"Cetuximab is a monoclonal antibody that binds to and blocks the epidermal growth factor receptor (EGFR), preventing ligand-induced activation and downstream proliferation signaling in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:56.919Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (KRAS wild-type)"},{"name":"Squamous cell carcinoma of the head and neck"},{"name":"Non-small cell lung cancer (EGFR-expressing)"}]},"trialDetails":[{"nctId":"NCT06102902","phase":"PHASE1","title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-05","conditions":"Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06599502","phase":"PHASE1","title":"A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-10-18","conditions":"Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":17},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07020221","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer","enrollment":295},{"nctId":"NCT07217028","phase":"PHASE1","title":"Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-04","conditions":"SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT04290546","phase":"PHASE1","title":"CIML NK Cell in Head & Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-20","conditions":"Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT05358249","phase":"PHASE1, PHASE2","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-10-24","conditions":"KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung","enrollment":74},{"nctId":"NCT06369259","phase":"PHASE2","title":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-24","conditions":"Advanced Colorectal Cancer","enrollment":33},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT02979977","phase":"PHASE2","title":"Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-03-24","conditions":"Squamous Cell Cancers of the Head and Neck","enrollment":50},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT03082534","phase":"PHASE2","title":"Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-03-28","conditions":"HNSCC, Lip SCC, Oral Cavity Cancer","enrollment":78},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT05002270","phase":"PHASE1, PHASE2","title":"JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation","status":"COMPLETED","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2021-09-03","conditions":"Advanced Solid Tumor, NSCLC, CRC","enrollment":29},{"nctId":"NCT07327411","phase":"PHASE2","title":"Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-27","conditions":"Advanced Refractory Solid Tumors","enrollment":40},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT04616183","phase":"PHASE1, PHASE2","title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-02","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":46},{"nctId":"NCT04009681","phase":"PHASE1, PHASE2","title":"A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","status":"TERMINATED","sponsor":"Synthorx, Inc, a Sanofi company","startDate":"2019-06-20","conditions":"Metastasis","enrollment":175},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT01552434","phase":"PHASE1","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03-16","conditions":"Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma","enrollment":155},{"nctId":"NCT05271604","phase":"PHASE2","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2022-12-13","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":42},{"nctId":"NCT05694936","phase":"PHASE2","title":"Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2023-01-23","conditions":"Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT01787500","phase":"PHASE1","title":"Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-15","conditions":"BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT01393821","phase":"NA","title":"Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-23","conditions":"Dermatologic Complications, Malignant Neoplasm, Pain","enrollment":27},{"nctId":"NCT04495621","phase":"PHASE1, PHASE2","title":"MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2020-07-20","conditions":"Metastatic Colorectal Cancer","enrollment":29},{"nctId":"NCT03428958","phase":"PHASE1, PHASE2","title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","status":"COMPLETED","sponsor":"NuCana plc","startDate":"2018-10-05","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":111},{"nctId":"NCT03646461","phase":"PHASE2","title":"Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2018-10-17","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":5},{"nctId":"NCT04800822","phase":"PHASE1","title":"PF-07284892 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-03-17","conditions":"Solid Tumor","enrollment":53},{"nctId":"NCT03115567","phase":"PHASE2","title":"A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-02-16","conditions":"Acneiform Rash, Papulopustular Eruption","enrollment":14},{"nctId":"NCT05143099","phase":"PHASE2","title":"Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-02-01","conditions":"Colorectal Neoplasms","enrollment":35},{"nctId":"NCT04359199","phase":"","title":"QUantitative Assessment of Swallowing After Radiation (QUASAR)","status":"UNKNOWN","sponsor":"Loren Mell, MD","startDate":"2020-09-01","conditions":"Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia","enrollment":42},{"nctId":"NCT01416688","phase":"","title":"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2011-11-15","conditions":"Colorectal Cancer, Dermatologic Complications, Lung Cancer","enrollment":146},{"nctId":"NCT01892527","phase":"PHASE2","title":"Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects","status":"COMPLETED","sponsor":"Armando Santoro, MD","startDate":"2013-03","conditions":"Colorectal Cancer Metastatic, C-met Overexpression","enrollment":43},{"nctId":"NCT03319459","phase":"PHASE1","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2018-01-18","conditions":"HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT01097642","phase":"PHASE2","title":"Neo-Adjuvant Study in Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2008-10-10","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04872634","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment","status":"UNKNOWN","sponsor":"NKMAX Co., Ltd.","startDate":"2021-07-08","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT01719380","phase":"PHASE2","title":"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11-23","conditions":"Colorectal Cancer","enrollment":156},{"nctId":"NCT03552406","phase":"PHASE1","title":"Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"ISU Abxis Co., Ltd.","startDate":"2018-04-27","conditions":"Solid Tumor","enrollment":33},{"nctId":"NCT02164916","phase":"PHASE2","title":"S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-11","conditions":"Colorectal Cancer","enrollment":106},{"nctId":"NCT01602315","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11-12","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":179},{"nctId":"NCT00851877","phase":"PHASE1, PHASE2","title":"Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-03-01","conditions":"Head and Neck Cancer","enrollment":37},{"nctId":"NCT01867294","phase":"PHASE2","title":"Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2012-08-31","conditions":"Advanced Malignant Neoplasm, Dermatologic Complication","enrollment":19},{"nctId":"NCT00343083","phase":"PHASE2","title":"Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-12","conditions":"Cancer of Head and Neck","enrollment":43},{"nctId":"NCT02205398","phase":"PHASE1","title":"Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-07-28","conditions":"Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer","enrollment":13},{"nctId":"NCT03666325","phase":"PHASE2","title":"Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2018-10-01","conditions":"Skin Neoplasm","enrollment":43},{"nctId":"NCT00954512","phase":"PHASE1, PHASE2","title":"Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Neoplasms","enrollment":15},{"nctId":"NCT00326495","phase":"PHASE2","title":"BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-05-10","conditions":"Metastatic Colorectal Cancer","enrollment":51},{"nctId":"NCT01874171","phase":"PHASE3","title":"Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC","status":"UNKNOWN","sponsor":"University of Warwick","startDate":"2012-11-15","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":334},{"nctId":"NCT01758575","phase":"","title":"Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2012-11","conditions":"Advanced or Metastatic Solid Malignancy","enrollment":8},{"nctId":"NCT01256385","phase":"PHASE2","title":"Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11","conditions":"Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma","enrollment":86},{"nctId":"NCT00091247","phase":"NA","title":"Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-12","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":130},{"nctId":"NCT00492206","phase":"PHASE2","title":"Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-06","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":40},{"nctId":"NCT00362986","phase":"PHASE3","title":"Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-10","conditions":"Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":116},{"nctId":"NCT01522612","phase":"PHASE2","title":"Colorectal Cancer (CRC) Cetuximab Elderly Frail","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-04","conditions":"Colorectal Cancer Metastatic","enrollment":5},{"nctId":"NCT00903734","phase":"PHASE1","title":"An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-04","conditions":"Advanced Cancers","enrollment":16},{"nctId":"NCT01198535","phase":"PHASE1","title":"Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09","conditions":"Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma","enrollment":60},{"nctId":"NCT00498992","phase":"NA","title":"Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer","status":"UNKNOWN","sponsor":"Ingalls Memorial Hospital","startDate":"2006-07","conditions":"Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":20},{"nctId":"NCT00694603","phase":"PHASE2","title":"Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy","status":"TERMINATED","sponsor":"Lecia V. Sequist","startDate":"2006-09","conditions":"Non-small Cell Lung Cancer","enrollment":56},{"nctId":"NCT00910676","phase":"PHASE2","title":"Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-10","conditions":"Metastatic Colorectal Cancer, Non-Small-Cell Lung Carcinoma","enrollment":30},{"nctId":"NCT00552149","phase":"PHASE2","title":"Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2007-10","conditions":"Advanced Biliary Cancer","enrollment":150},{"nctId":"NCT00820417","phase":"PHASE1","title":"Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib","status":"COMPLETED","sponsor":"Harrison Clinical Research","startDate":"2004-06","conditions":"Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)","enrollment":63},{"nctId":"NCT00536614","phase":"PHASE2","title":"Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2005-05","conditions":"Pancreatic Cancer","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":319,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cetuximab (EGFR inhibitor)","genericName":"Cetuximab (EGFR inhibitor)","companyName":"Vanderbilt-Ingram Cancer Center","companyId":"vanderbilt-ingram-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetuximab is a monoclonal antibody that binds to and blocks the epidermal growth factor receptor (EGFR), preventing ligand-induced activation and downstream proliferation signaling in cancer cells. Used for Metastatic colorectal cancer (KRAS wild-type), Squamous cell carcinoma of the head and neck, Non-small cell lung cancer (EGFR-expressing).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}